Multiple Myeloma Research Foundation (MMRF) Supports Tom Brokaw and All Patients Through Their Journey with Multiple Myeloma

Norwalk, CT — February 11, 2014

The Multiple Myeloma Research Foundation (MMRF) supports Tom Brokaw and all patients through their journey with myeloma.

“Our hearts go out to Tom and his family during this time,” said Kathy Giusti, MMRF Founder and CEO and a multiple myeloma patient. “Fortunately, in recent years, we have seen tremendous advancements in treating multiple myeloma and are committed to continued and rapid progress toward a cure.”

As a result of the work accomplished alongside our long-standing partners at academic centers, community medical centers and the pharmaceutical and biotechnology industry worldwide, there is tremendous cause for hope.

To learn more about multiple myeloma or the MMRF, please visit: www.themmrf.org or call 866-603-6628.

About Multiple Myeloma
Multiple myeloma is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 24,050 adults (13,500 men and 10,550 women) in the United States will be diagnosed with multiple myeloma in 2014 and an estimated 11,090 people are predicted to die from the disease. The five-year survival rate for multiple myeloma is approximately 43%, versus 28% in 1998.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised $250 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency.